Trial reportEuropean heart journal2018
Systemic microvascular dysfunction in microvascular and vasospastic angina.
Trial report in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CORonary MICrovascular Angina (CorMicA): a Randomised, Controlled, Pilot Trial
The Clinical Utility Of Cardiac Magnetic Resonance Imaging in Patients With Angina But No Obstructive Coronary Disease (CorCMR): A Diagnostic Study And Nested Randomised Trial
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- Pooled it
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.Circulation · 2024Trial
- Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.European heart journal · 2020Trial
- 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA).JACC. Cardiovascular interventions · 2020 · on this mapTrial
- Effect of sarpogrelate and high-dose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study.Clinical cardiology · 2019Trial
- Coronary Microvascular Dysfunction: Epidemiology, Pathophysiology, Diagnosis, and Treatment.MedComm · 2026Review
- Covert macrovascular disease and early outcome after ischemic cerebrovascular events.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Observational
- Clinical Significance of High-Sensitivity Cardiac Troponin I and Myoglobin in Patients with Suspected Coronary Microvascular Dysfunction.Journal of cardiovascular translational research · 2026Article
- Coronary microvascular dysfunction: a narrative review.Cardiovascular diagnosis and therapy · 2026Review
- Coronary Artery Spasm in Patients with Type 2 Diabetes Mellitus.Life (Basel, Switzerland) · 2026Review
- Relationship between epicardial fat tissue, endothelial function, and coronary flow reserve in coronary microvascular disease patients.Cardiovascular ultrasound · 2026Article
- Lipidomic Profiling and Biological Aging in Patients with Coronary Microvascular Dysfunction.Vascular health and risk management · 2026Article
- Vasospastic angina: Pathophysiology, diagnosis, and emerging therapeutic approaches.World journal of cardiology · 2025Review
- Redox Regulation of Microvascular Physiology and Pathophysiology: Insights into Therapeutic Strategies and Limitations.Antioxidants & redox signaling · 2025Review
- Brain‑heart axis: Neurostimulation techniques in ischemic heart disease (Review).International journal of molecular medicine · 2025Review
- Prevalence of Angina Pectoris: An Analysis of the National Health Interview Survey (NHIS) Database.Cureus · 2025Article
- Integrated analysis of genetic, proteinic, and metabolomic alterations in Behcet's disease.Scientific reports · 2025Article
- Exploring coronary microvascular dysfunction from functional impairment and structural damage.Frontiers in cardiovascular medicine · 2025Review
- Coronary microvascular dysfunction is a hallmark of all subtypes of MINOCA.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Cardiac Arrests Due to Medically Refractory Coronary Vasospasm in the Acute Cardiac Care Unit.CJC open · 2024Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 2 countries.
Funding
Abstract
Aims: Coronary microvascular dysfunction and/or vasospasm are potential causes of ischaemia in patients with no obstructive coronary artery disease (INOCA). We tested the hypothesis that these patients also have functional abnormalities in peripheral small arteries. Methods and results: Patients were prospectively enrolled and categorised as having microvascular angina (MVA), vasospastic angina (VSA) or normal control based on invasive coronary artery function tests incorporating probes of endothelial and endothelial-independent function (acetylcholine and adenosine). Gluteal biopsies of subcutaneous fat were performed in 81 subjects (62 years, 69% female, 59 MVA, 11 VSA, and 11 controls). Resistance arteries were dissected enabling study using wire myography. Maximum relaxation to ACh (endothelial function) was reduced in MVA vs. controls [median 77.6 vs. 98.7%; 95% confidence interval (CI) of difference 2.3-38%; P = 0.0047]. Endothelium-independent relaxation [sodium nitroprusside (SNP)] was similar between all groups. The maximum contractile response to endothelin-1 (ET-1) was greater in MVA (median 121%) vs. controls (100%; 95% CI of median difference 4.7-45%, P = 0.015). Response to the thromboxane agonist, U46619, was also greater in MVA (143%) vs. controls (109%; 95% CI of difference 13-57%, P = 0.003). Patients with VSA had similar abnormal patterns of peripheral vascular reactivity including reduced maximum relaxation to ACh (median 79.0% vs. 98.7%; P = 0.03) and increased response to constrictor agonists including ET-1 (median 125% vs. 100%; P = 0.02). In all groups, resistance arteries were ≈50-fold more sensitive to the constrictor effects of ET-1 compared with U46619. Conclusions: Systemic microvascular abnormalities are common in patients with MVA and VSA. These mechanisms may involve ET-1 and were characterized by endothelial dysfunction and enhanced vasoconstriction. Clinical trial registration: ClinicalTrials.gov registration is NCT03193294.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.